News AbbVie bids to join the BCMA crowd with etentamig AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.
News AbbVie's cancer TCE etentamig hits the mark in myeloma AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?
News Roche joins the oral SERD club as FDA clears Wilserdly Roche is the latest drugmaker to bring an oral SERD drug for breast cancer to the US market, after getting FDA approval for its Wilserdly product.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.